Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders
Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger,
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …
cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action
SH Francis, JL Busch, JD Corbin - Pharmacological reviews, 2010 - ASPET
To date, studies suggest that biological signaling by nitric oxide (NO) is primarily mediated
by cGMP, which is synthesized by NO-activated guanylyl cyclases and broken down by …
by cGMP, which is synthesized by NO-activated guanylyl cyclases and broken down by …
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
HA Ghofrani, IH Osterloh, F Grimminger - Nature reviews Drug …, 2006 - nature.com
In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has
evolved from a potential anti-angina drug to an on-demand oral treatment for erectile …
evolved from a potential anti-angina drug to an on-demand oral treatment for erectile …
Clinical and molecular genetics of the phosphodiesterases (PDEs)
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure
R Kamel, J Leroy, G Vandecasteele… - Nature Reviews …, 2023 - nature.com
Cyclic nucleotide phosphodiesterases (PDEs) modulate the neurohormonal regulation of
cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes …
cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes …
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
Abstract The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra™),
vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile …
vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile …
Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
AD Bondarev, MM Attwood, J Jonsson… - Frontiers in …, 2022 - frontiersin.org
The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal
transduction system, are long-established as attractive therapeutic targets. During …
transduction system, are long-established as attractive therapeutic targets. During …
The ubiquitous role of nitric oxide in cardioprotection
In recent years, major advances have been made toward understanding the role of nitric
oxide (NO) in the ischemic biology of the heart. It is now clear that NO, either endogenous or …
oxide (NO) in the ischemic biology of the heart. It is now clear that NO, either endogenous or …
Evidence for Mitochondrial K+ Channels and Their Role in Cardioprotection
B O'Rourke - Circulation research, 2004 - Am Heart Assoc
Twenty years after the discovery of sarcolemmal ATP-sensitive K+ channels and 12 years
after the discovery of mitochondrial KATP (mitoKATP) channels, progress has been …
after the discovery of mitochondrial KATP (mitoKATP) channels, progress has been …
Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of nitric oxide signaling
We investigated the effect of sildenafil in protection against necrosis or apoptosis in
cardiomyocytes. Adult mouse ventricular myocytes were treated with sildenafil (1 or 10 μm) …
cardiomyocytes. Adult mouse ventricular myocytes were treated with sildenafil (1 or 10 μm) …